Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Jang, Kee-Taek, Lee, Jeeyun, Jang, Heung-Moon, Choi, Hye-Jin, Jang, Hye-Lim, Park, Se Hoon, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350637/
https://www.ncbi.nlm.nih.gov/pubmed/25749176
http://dx.doi.org/10.1016/j.tranon.2014.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350637/
https://www.ncbi.nlm.nih.gov/pubmed/25749176
http://dx.doi.org/10.1016/j.tranon.2014.12.003

Ejemplares similares